Advocacy & Compliance

Healthesystems’ Advocacy & Compliance experts are essential in the management of pharmacy and ancillary benefits for our clients. By tracking and influencing regulatory activity, our team stays ahead of evolving trends and identifies opportunities to advocate on behalf of our clients, their injured workers, and the broader industry.

Go to Regulatory Recap News

Subscribe for Weekly Updates

The Advocacy &  Compliance Team

Monitors and reports on proposed and pending regulatory changes that impact workers' comp, helping shape effective program strategies

Advocates for fair and balanced public policy through proactive engagement with regulators, customers, and other stakeholders throughout the rulemaking lifecycle

Supports operational compliance by providing guidance to internal stakeholders and external partners during the implementation of new regulatory changes

Regulatory Recap

A weekly e-newsletter informed by the Advocacy & Compliance team to help keep our clients and industry contacts in the know on the latest legislation and policy updates impacting workers’ comp.

Subscribe

Industry Data

NCCI Publishes Labor Market Insight Report

The report covers trend in employment growth, wages, and sectors most impacted.

Read More →

January 27, 2025

Industry Data

WCRI Explores the Lifecycle of Claims in New York

The study examines overall claim cost, timing of key indemnity payments, and other system performance indicators.

Read More →

January 27, 2025

Mental Health Presumptions

New York, Oklahoma, Oregon, and Washington Propose Updates to PTSD Presumptions

The updates vary across each state and for different occupations, but the trend of more PTSD presumptions around the country continues.

Read More →

January 27, 2025

Cost Containment

Hawaii Bill Could Cap Nonprescription Drugs Reimbursement

The bill would cap nonprescription, over the counter, and non-legend drug reimbursements at the drug’s cost plus 40%.

Read More →

January 27, 2025

Presumptions

Four States Consider Expanding Cancer Presumptions

Connecticut, Hawaii, Mississippi & Nebraska each introduced bills that would create or expand cancer presumptions.

Read More →

January 27, 2025

Access to Care Cost Containment

Arizona Proposes Employer Pharmacy Network Bill

If passed, employees would be required to use network pharmacies effective December 31, 2025.

Read More →

January 27, 2025

Presumptions

Virginia Considers Making Repetitive Trauma an Occupational Illness

The bill would apply when repetitive and sustained physical stress have occurred over a period of time.

Read More →

January 20, 2025

Cost Containment

Illinois Bill Aims to Limit Custom Compound Reimbursements

If passed, the bill would limit reimbursements to a one-time, seven-day supply if no commercial equivalent exists.

Read More →

January 20, 2025

Psychedelics

Psychedelic Bills in Colorado, New Hampshire, New York, Virginia, and Washington

Five different states are proposing legislation for psychedelic therapy or legalized use for the treatment of PTSD and other mental illnesses.

Read More →

January 20, 2025

« Previous 1 … 27 28 29 30 31 … 41 Next »

Subscribe to Regulatory Recap

Get weekly legislation & policy updates straight to your inbox.

hello world!

Further resources you may be interested in

Additional articles and updates from Healthesystems related to policy shaping workers’ comp.

COVID-19 Mutations Impact Testing

False negatives may be reported due to genetic variations of the virus.

Worker Classification Debate Continues Across the Country

The Department of Labor issued a new rule while special interest groups push for regulatory change.

The Department of Justice Sues Walmart Over Role in Opioid Crisis

Alleged violations of the Controlled Substances Act could result in billions of dollars in penalties.

Top 10 Disruptors of 2020 for the Workers’ Comp Industry

Initial insights from Healthesystems’ annual industry survey.

FDA Authorizes Two COVID-19 Vaccines, At-Home Test, More Treatments

Vaccine candidates from Pfizer-BioNTech and Moderna received EUAs, as did the first at-home test that delivers results in 30 minutes, and two treatments for the virus.